NCI Advanced Renal Cell Cancer-Improving First Line Treatment
February 16–17, 2013
National Cancer Institute's
GU Steering Committee and Renal Cancer Task Force Committee Chairs:
Chris Kane, M.D
Victor Reuter, M.D.
Brian Rini, M.D
- Review the clinical trial and translational science data with VEGF-targeted and mTOR-targeted therapy for patients with advanced RCC.
- Define clinical and translational questions that need to be addressed in clinical trials to improve the initial therapy of advanced RCC patients.
- Develop novel biomarker based clinical trials.
Persons With Special Needs
The National Cancer Institute and NOVA Research Company understand the importance of providing individuals with the materials and accommodations they need to have an enjoyable conference experience.
With advance notice, we can provide assistance if you have special needs. Please contact us so we may serve you better.
Please be sure to let us know of any provisions we can make on your behalf by contacting Mahogany Hopkins at 301-986-1891, ext. 155. You may also e-mail your concerns to firstname.lastname@example.org.